BREAKING
NVIDIA (NVDA) eyes China AI chip re-entry as export licensing shifts to case-by-case review 3 days ago Qualcomm (QCOM) authorizes $20B stock repurchase program, raises quarterly dividend to $0.92 3 days ago UP Fintech Holding Limited Reports Strong 2025 Results 3 days ago FedEx (FDX) Q3 Earnings Crush Estimates: EPS of $5.25 Beats by 27% on $24B Revenue 3 days ago Cato Corporation 2025 Financial Results Summary 3 days ago GROY Posts Breakeven Q4 Earnings, Beating Estimates by 100% as Revenue Grows 34.2% YoY to $4.5M 3 days ago York Space Systems (YSS) Posts -$0.24 EPS vs. -$0.18 Est., Revenue Soars to $105.3M 3 days ago Scholastic (SCHL) Q3 Loss Narrows to $0.15/Share vs $0.36 Estimate, Revenue Misses at $329.1M 3 days ago Curis (CRIS) EPS Soars 210.8% to $1.23, But Revenue Plunges 67.1% to $1.1M 3 days ago Eton Pharmaceuticals (ETON) Q4 Revenue Surges 82.9% YoY to $21.3M, EPS Climbs 266.7% 3 days ago NVIDIA (NVDA) eyes China AI chip re-entry as export licensing shifts to case-by-case review 3 days ago Qualcomm (QCOM) authorizes $20B stock repurchase program, raises quarterly dividend to $0.92 3 days ago UP Fintech Holding Limited Reports Strong 2025 Results 3 days ago FedEx (FDX) Q3 Earnings Crush Estimates: EPS of $5.25 Beats by 27% on $24B Revenue 3 days ago Cato Corporation 2025 Financial Results Summary 3 days ago GROY Posts Breakeven Q4 Earnings, Beating Estimates by 100% as Revenue Grows 34.2% YoY to $4.5M 3 days ago York Space Systems (YSS) Posts -$0.24 EPS vs. -$0.18 Est., Revenue Soars to $105.3M 3 days ago Scholastic (SCHL) Q3 Loss Narrows to $0.15/Share vs $0.36 Estimate, Revenue Misses at $329.1M 3 days ago Curis (CRIS) EPS Soars 210.8% to $1.23, But Revenue Plunges 67.1% to $1.1M 3 days ago Eton Pharmaceuticals (ETON) Q4 Revenue Surges 82.9% YoY to $21.3M, EPS Climbs 266.7% 3 days ago
ADVERTISEMENT
Market News

Onconova Therapeutics (ONTX): FY2019 Earnings Snapshot

— Onconova Therapeutics (NASDAQ: ONTX) reported FY2019 net loss of $1.49 per share, vs. $4.99 per share last year. — Net loss was $21.5 million compared to $20.4 million last year.  — Research and development expenses were $15.5 million versus $16.9 million for 2018.  — Cash and cash equivalents as of December 31, 2019, totaled […]

March 25, 2020 1 min read

— Onconova Therapeutics (NASDAQ: ONTX) reported FY2019 net loss of $1.49 per share, vs. $4.99 per share last year. — Net loss was $21.5 million compared to $20.4 million last year.  — Research and development expenses were $15.5 million versus $16.9 million for 2018.  — Cash and cash equivalents as of December 31, 2019, totaled […]

— Onconova Therapeutics (NASDAQ: ONTX) reported FY2019 net
loss of $1.49 per share, vs. $4.99 per share last year.

— Net loss was $21.5 million compared to $20.4 million last
year. 

— Research and development expenses were $15.5 million versus
$16.9 million for 2018. 

— Cash and cash equivalents as of December 31, 2019,
totaled $22.7 million, compared to $17 million as of December 31, 2018. 

ADVERTISEMENT